STAT+: An awkward moment for Pfizer’s Bourla in Washington
The Pfizer CEO at the White House, CDC vaccine efforts, and other crucial biotech news.
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Hello! Today, we see the CDC’s path forward with vaccines starting to look more complicated, take note of the cold reception Pfizer CEO Albert Bourla got at the White House, and more.
Bluebird Bio sells itself to investment firms, avoids bankruptcy
From STAT’s Jason Mast: Bluebird Bio announced this morning it would sell itself and its portfolio of gene therapies to the investment firms Carlyle and SK Capital for less than $30 million, in a deal that lets the beleaguered biotech avoid bankruptcy.
